Immunohistochemical expression of four different stem cell markers in prostate cancer: High expression of NANOG in conjunction with hypoxia-inducible factor-1α expression is involved in prostate epithelial malignancy

Oncology Letters

Volumn 8, Issue 3, 2014, Pages 985-992

  Miyazawa, Katsuhito ^a   Tanaka, Takuji ^b   Nakai, Dan ^a   Morita, Nobuyo ^a   Suzuki, Koji ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b Gifu Municipal Hospital   (Japan)

Author keywords

Cancer stem cell; Hypoxia inducible factor 1 ; NANOG; OCT4; Prostate cancer

Indexed keywords

CD133 ANTIGEN; CELL MARKER; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NESTIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG;

ARTICLE; CANCER GRADING; CANCER STEM CELL; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION;

EID: 84904269129     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2274     Document Type: Article

References (56)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun M: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W and Sobue T: Cancer incidence and incidence rates in Japan in 2002: based on data from 11 population-based cancer registries. Jpn J Clin Oncol 38: 641-648, 2008.
3. Nonn L, Ananthanarayanan V and Gann PH: Evidence for field cancerization of the prostate. Prostate 69: 1470-1479, 2009.
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003.
5. Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951, 2005.
6. O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110, 2007.
7. Gu G, Yuan J, Wills M and Kasper S: Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 67: 4807-4815, 2007.
8. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S and Rhim JS: Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67: 3153-3161, 2007.
9. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S and Smith A: Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 113: 643-655, 2003.
10. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M and Yamanaka S: The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113: 631-642, 2003.
11. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH and Nephew KP: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: 4311-4320, 2008.
12. Santagata S, Ligon KL and Hornick JL: Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol 31: 836-845, 2007.
13. Gong C, Liao H, Guo F, Qin L and Qi J: Implication of expression of Nanog in prostate cancer cells and their stem cells. J Huazhong Univ Sci Technolog Med Sci 32: 242-246, 2012.
14. Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Stokke T, Nesland JM and Suo Z: Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One 6: e29170, 2011.
15. Scholer HR, Hatzopoulos AK, Balling R, Suzuki N and Gruss P: A family of octamer-specific proteins present during mouse embryogenesis: evidence for germline-specific expression of an Oct factor. EMBO J 8: 2543-2550, 1989.
16. Boiani M and Scholer HR: Regulatory networks in embryo-derived pluripotent stem cells. Nat Rev Mol Cell Biol 6: 872-884, 2005.
17. Monk M and Holding C: Human embryonic genes re-expressed in cancer cells. Oncogene 20: 8085-8091, 2001.
18. Ugolkov AV, Eisengart LJ, Luan C and Yang XJ: Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate 71: 18-25, 2011.
19. Mallanna SK and Rizzino A: Systems biology provides new insights into the molecular mechanisms that control the fate of embryonic stem cells. J Cell Physiol 227: 27-34, 2012.
20. Tysnes BB: Tumor-initiating and-propagating cells: cells that we would like to identify and control. Neoplasia 12: 506-515, 2010.
21. Till JE: Stem cells in differentiation and neoplasia. J Cell Physiol Suppl 1: 3-11, 1982.
22. Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D and Kunz-Schughart LA: CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol 229: 355-378, 2013.
23. Missol-Kolka E, Karbanova J, Janich P, Haase M, Fargeas CA, Huttner WB and Corbeil D: Prominin-1 (CD133) is not restricted to stem cells located in the basal compartment of murine and human prostate. Prostate 71: 254-267, 2011.
24. Lendahl U, Zimmerman LB and McKay RD: CNS stem cells express a new class of intermediate filament protein. Cell 60: 585-595, 1990.
25. Ishiwata T, Matsuda Y and Naito Z: Nestin in gastrointestinal and other cancers: effects on cells and tumor angiogenesis. World J Gastroenterol 17: 409-418, 2011.
26. Kleeberger W, Bova GS, Nielsen ME, Herawi M, Chuang AY, Epstein JI and Berman DM: Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer Res 67: 9199-9206, 2007.
27. Sotomayor P, Godoy A, Smith GJ and Huss WJ: Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. Prostate 69: 401-410, 2009.
28. Kimbro KS and Simons JW: Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 13: 739-749, 2006.
29. Mabjeesh NJ and Amir S: Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol 22: 559-572, 2007.
30. Bao B, Ahmad A, Kong D, Ali S, Azmi AS, Li Y, Banerjee S, Padhye S and Sarkar FH: Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One 7: e43726, 2012.
31. Mathieu J, Zhang Z, Zhou W, Wang AJ, Heddleston JM, Pinna CM, Hubaud A, Stadler B, Choi M, Bar M, et al: HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 71: 4640-4652, 2011.
32. Salnikov AV, Liu L, Platen M, Gladkich J, Salnikova O, Ryschich E, Mattern J, Moldenhauer G, Werner J, Schemme P, et al: Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential. PLoS One 7: e46391, 2012.
33. Clark AT: The stem cell identity of testicular cancer. Stem Cell Rev 3: 49-59, 2007.
34. Cizkova D, Soukup T and Mokry J: Nestin expression reflects formation, revascularization and reinnervation of new myofibers in regenerating rat hind limb skeletal muscles. Cells Tissues Organs 189: 338-347, 2009.
35. Horst D, Kriegl L, Engel J, Kirchner T and Jung A: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99: 1285-1289, 2008.
36. Chambers I and Tomlinson SR: The transcriptional foundation of pluripotency. Development 136: 2311-2322, 2009.
37. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A and Weinberg RA: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507, 2008.
38. Ezeh UI, Turek PJ, Reijo RA and Clark AT: Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 104: 2255-2265, 2005.
39. Li L, Yu H, Wang X, Zeng J, Li D, Lu J, Wang C, Wang J, Wei J, Jiang M and Mo B: Expression of seven stem-cell-associated markers in human airway biopsy specimens obtained via fiberoptic bronchoscopy. J Exp Clin Cancer Res 32: 28, 2013.
40. Luo W, Li S, Peng B, Ye Y, Deng X and Yao K: Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma. PLoS One 8: e56324, 2013.
41. Yin X, Li YW, Zhang BH, Ren ZG, Qiu SJ, Yi Y and Fan J: Coexpression of stemness factors Oct4 and Nanog predict liver resection. Ann Surg Oncol 19: 2877-2887, 2012.
42. English HF, Santen RJ and Isaacs JT: Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 11: 229-242, 1987.
43. Lawson DA and Witte ON: Stem cells in prostate cancer initiation and progression. J Clin Invest 117: 2044-2050, 2007.
44. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB and Farrar WL: CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 98: 756-765, 2008.
45. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, et al: Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920, 2007.
46. Pan G and Thomson JA: Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res 17: 42-49, 2007.
47. Pereira L, Yi F and Merrill BJ: Repression of Nanog gene transcription by Tcf3 limits embryonic stem cell self-renewal. Mol Cell Biol 26: 7479-7491, 2006.
48. Suzuki A, Raya A, Kawakami Y, Morita M, Matsui T, Nakashima K, Gage FH, Rodríguez-Esteban C and Izpisúa Belmonte JC: Maintenance of embryonic stem cell pluripotency by Nanog-mediated reversal of mesoderm specification. Nat Clin Pract Cardiovasc Med 3 (Suppl 1): S114-S122, 2006.
49. Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, Chou SH, Chien CS, Ku HH and Lo JF: Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 14: 4085-4095, 2008.
50. Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, Liu C, Calhoun-Davis T, Zaehres H, Daley GQ and Tang DG: Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 27: 993-1005, 2009.
51. Xu RH, Sampsell-Barron TL, Gu F, Root S, Peck RM, Pan G, Yu J, Antosiewicz-Bourget J, Tian S, Stewart R and Thomson JA: NANOG is a direct target of TGFbeta/activin-mediated SMAD signaling in human ESCs. Cell Stem Cell 3: 196-206, 2008.
52. Danielpour D: Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. Eur J Cancer 41: 846-857, 2005.
53. Pesce M and Scholer HR: Oct-4: control of totipotency and germline determination. Mol Reprod Dev 55: 452-457, 2000.
54. Zangrossi S, Marabese M, Broggini M, Giordano R, D'Erasmo M, Montelatici E, Intini D, Neri A, Pesce M, Rebulla P and Lazzari L: Oct-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker. Stem Cells 25: 1675-1680, 2007.
55. Lekas A, Lazaris AC, Deliveliotis C, Chrisofos M, Zoubouli C, Lapas D, Papathomas T, Fokitis I and Nakopoulou L: The expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and angiogenesis markers in hyperplastic and malignant prostate tissue. Anticancer Res 26: 2989-2993, 2006.
56. Makarewicz R, Zyromska A and Andrusewicz H: Comparative analysis of biological profiles of benign prostate hyperplasia and prostate cancer as potential diagnostic, prognostic and predictive indicators. Folia Histochem Cytobiol 49: 452-457, 2011.